Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Donald Aspenson

Endocrinology, Diabetes & Metabolism Tulsa, OK Medical Doctor

NPI 1225008550 CMS profile 282690

8921 S Mingo Rd, Suite 200, Tulsa, OK 74133

Open in the dashboard

General payments

$153,303

349 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Donald Aspenson of Tulsa, OK is reported in the CMS Open Payments database as having received $153,303 across 349 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $14,197 42
2021 General $8,287 32
2020 General $26,239 52
2019 General $104,580 223

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Aspenson
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Donald Aspenson were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Donald Aspenson Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $104,580 $494 $123–$2,253 $163
2020 $26,239 $335 $85–$1,841 $114
2021 $8,287 $398 $88–$1,981 $132
2022 $14,197 $364 $88–$1,568 $149
2023 $0 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Novo Nordisk Inc $54,944 81 payments
  2. Merck Sharp & Dohme Corporation $36,936 58 payments
  3. Amgen Inc. $24,129 37 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $14,409 39 payments
  5. Lilly USA, LLC $13,747 48 payments
  6. AstraZeneca Pharmaceuticals LP $5,693 24 payments
  7. Janssen Pharmaceuticals, Inc $2,488 10 payments
  8. Abbott Laboratories $221 4 payments
  9. Antares Pharma, Inc. $86 6 payments
  10. Regeneron Healthcare Solutions, Inc. $78 5 payments
  11. Other $573 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $136,411 73 payments
  2. Travel and Lodging $8,058 58 payments
  3. Food and Beverage $5,884 214 payments
  4. Consulting Fee $2,925 1 payment
  5. Education $26 3 payments
Products named General payments · program years 2019–2022
  1. STEGLATRO $36,915 56 payments
  2. RYBELSUS $21,760 25 payments
  3. Ozempic $20,874 31 payments
  4. Prolia $17,802 21 payments
  5. JARDIANCE Diabetes $14,409 39 payments
  6. JARDIANCE Diabetes $13,598 36 payments
  7. Tresiba $7,441 10 payments
  8. EVENITY $6,319 17 payments
  9. FARXIGA $5,693 24 payments
  10. INVOKANA $2,388 8 payments
  11. Other $1,868 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record